Floatz logo

mln9708

Lymphoma, T-Cell, Peripheral

CellCentric Ltd.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Lymphoma, T-Cell, Peripheral cohort.

Asset / SponsorPhaseRating
Romidepsin
University of Virginia
Phase 3BBB
Eloxatin
The Lymphoma Academic Research Organisation
Phase 2BB
Calcium folinate pentahydrate
Fox Chase Cancer Center
Phase 2BB
PEGFILGRASTIM
City of Hope Medical Center
Phase 2B
Tenalisib
Rhizen Pharmaceuticals SA
Phase 2B

View all 16 →

Same molecule, other indications

mln9708 is also rated in:

Multiple MyelomaDormant
BB
Indicative ·
66 / 100
View asset →
AmyloidosisDormant
BB
Indicative ·
64 / 100
View asset →
Higher-risk Myelodysplastic SyndromeDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →